More detail on unusually rosy statin trial results, industry influence alleged
- From: Susan <nothanks@xxxxxxxxxxxx>
- Date: Mon, 04 Oct 2010 16:24:29 -0400
Sue Hughes. JUPITER criticism addressed again in more detail . theheart.org. [Clinical Conditions > Lipid/Metabolic > Lipid/Metabolic]; Oct 1, 2010. Accessed at http://www.theheart.org/article/1130113.do on Oct 4, 2010
"Dr Sanjay Kaul (Cedars Sinai Medical Center, Los Angeles), author of one of the original Archives papers, said he could only address the three major points raised in his article: that treatment decisions should not be stratified by hs-CRP because there was no low hs-CRP arm in JUPITER; that the large risk reductions were due to the early stopping of the trial; and that diet, exercise, weight loss, and risk-factor control trumps pharmacologic intervention for primary prevention. He notes that Ridker agrees with the third point, offers a partial rebuttal against the first, and strongly disagrees with the second."